Torrent Pharmaceuticals reported consolidated Q4 FY26 revenue of ₹4,197 Cr and total income of ₹4,180 Cr, driven by the acquisition of JB Pharma and strong base-business growth. Consolidated net profit after tax was ₹364 Cr in Q4 FY26 vs ₹498 Cr in Q4 FY25, after exceptional items of ₹66 Cr related to the JB Pharma acquisition. India and Brazil were key growth engines (India revenue ₹2,215 Cr, Brazil ₹455 Cr) while integration and acquisition-related costs plus higher finance costs weighed on PAT. The Board recommended a final dividend of ₹9 per share and the company completed large long-term...
